What's in SEBELA IRELAND LTD's pipeline?

SEBELA IRELAND LTD has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with SEBELA IRELAND LTD's portfolio?

Top competitors by shared drug class: Pfizer, Bausch Health, Bayer AG, , Mycovia Pharms.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sebela-ireland-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

SEBELA IRELAND LTD — Portfolio Competitive Intelligence Brief

SEBELA IRELAND LTD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Sporanox	itraconazole	marketed	Azole Antifungal [EPC]	C-X-C chemokine receptor type 1	Oncology	1992-01-01
Motofen	DIFENOXIN	marketed	Antidiarrheal	Mu-type opioid receptor	Pain	1978-01-01

Therapeutic area mix

Oncology · 1
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Bausch Health · 1 shared drug class
Bayer AG · 1 shared drug class
· 1 shared drug class
Mycovia Pharms · 1 shared drug class
Pfizer Inc. · 1 shared drug class
Johnson & Johnson (Janssen) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SEBELA IRELAND LTD:

Cite this brief

Drug Landscape (2026). SEBELA IRELAND LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sebela-ireland-ltd. Accessed 2026-05-16.